This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Dornase alfa" – news · newspapers · books · scholar · JSTOR(February 2022)
Dornase alfa
Clinical data
Trade names
Pulmozyme
AHFS/Drugs.com
Monograph
MedlinePlus
a694002
License data
US DailyMed: Dornase alfa
Pregnancy category
AU: B1[1]
Routes of administration
Inhalation
ATC code
R05CB13 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)[1]
CA: ℞-only / Schedule D[2]
US: ℞-only[3]
In general: ℞ (Prescription only)
Identifiers
CAS Number
143831-71-4N
DrugBank
DB00003Y
ChemSpider
none
UNII
953A26OA1Y
KEGG
D03896
CompTox Dashboard (EPA)
DTXSID801010888
ECHA InfoCard
100.029.685
Chemical and physical data
Formula
C1321H1999N339O396S9
Molar mass
29254.04 g·mol−1
NY (what is this?)(verify)
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]
^ abProduct guildlink.com.au
^"Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.
^ abcde"Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
Dornasealfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase)...
before kidney transplant due to chronic kidney disease. 1993: Pulmozyme (dornasealfa): Inhalation treatment for children and young adults with cystic fibrosis—recombinant...
Aerosolized medications that help loosen secretions include dornasealfa and hypertonic saline. Dornase is a recombinant human deoxyribonuclease, which breaks...
discontinued in 2004 in favor of its successor, Nutropin. Pulmozyme (dornasealfa), for the improvement of pulmonary function in cystic fibrosis. Raptiva...
beneficial in treating those with bronchiectasis. Mucolytic agents such as dornasealfa are not recommended for individuals with non-CF bronchiectasis. Mannitol...
Specifically, DNase I, also known as FDA approved drug Pulmozyme (also known as dornasealfa) is used as a treatment to increase pulmonary function. Other respiratory...
Global Information
(what is this?) (verify)